Relocating it from ER and autophagosome/lysosome locations necessitates phosphorylating the serine 441 residue and de-O-GlcNAcylation of five serine/threonine residues, respectively; for this reason, developing treatments for diseases associated with GRASP55, such as cystic fibrosis, lipid metabolic diseases, or cancers, would benefit from small-molecule compounds capable of inducing either phosphorylation or de-O-GlcNAcylation, thus activating GRASP55, which can be beneficial [141]. Here, GORASP2 is linked to cystic fibrosis.